Massive Bio Partners With FOMAT to Expand Cancer Patient Prescreening for Clinical Trial Access
AI-driven oncology company joins forces with the nation’s largest Embedded Research Organization to connect more cancer patients with life-changing clinical trials
Massive Bio, a global precision oncology company, today announced a partnership with FOMAT, the largest Embedded Research Organization (ERO) in the United States, to support AI-powered patient prescreening for oncology clinical trials. Launched in June 2026, the partnership supports patient prescreening across FOMAT's community-based research network, currently running a pilot project to test the efficiency of the integrated workflow before expanding its scope.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260720835336/en/ Massive Bio partners with FOMAT to expand AI-driven cancer patient prescreening, connecting more patients to clinical trial opportunities.
Despite significant advances in oncology research, the majority of cancer patients who could benefit from clinical trials never enroll, often because the connection between patients and available studies is fragmented, delayed, or simply never made. Prescreening, the process of identifying whether a patient may be eligible for a trial before committing to a full eligibility review, is one of the most critical and time-sensitive steps in that journey. When done well, it reduces burden on both patients and sites while accelerating the path to enrollment.
